GRI Bio, Inc. 8-K Summary
Business Context and Reporting Period
GRI Bio, Inc. filed this Current Report on Form 8-K on January 19, 2024, reporting the results of a virtual Special Meeting of Stockholders held the same day. The company’s common stock trades on the Nasdaq Capital Market under the symbol GRI. As of the December 18, 2023 record date, 4,520,233 common shares were issued and outstanding and eligible to vote.
Meeting Results and Key Corporate Action
| Proposal | For | Against | Abstained | Result |
|---|---|---|---|---|
| Reverse stock split amendment, at a ratio between 1-for-2 and 1-for-9, with the exact ratio determined by the Board | 1,158,012 | 817,185 | 2,247 | Approved |
| Postponement or adjournment to solicit additional proxies, if necessary | 1,252,187 | 716,895 | 8,362 | Approved |
A quorum of 1,977,444 shares, representing approximately 43.7% of eligible shares, was present or represented by proxy. No broker non-votes were reported.
Material Changes and Implications
- Stockholders authorized the Board to amend the certificate of incorporation to effect a reverse stock split within a 1-for-2 to 1-for-9 range.
- The Board retains sole discretion to determine the final reverse split ratio and may abandon the transaction without implementing it.
- The authorization does not reduce the number of authorized shares of common stock.
- The filing does not state whether the reverse stock split had been implemented as of January 19, 2024, nor does it provide a planned effective date or selected ratio.
Financial Metrics, Liquidity, and Outlook
This 8-K does not provide revenue, profit, cash flow, margin, debt, liquidity, or financial guidance information. It also does not include new management commentary, operating forecasts, contingencies, or unusual financial items beyond the approved potential reverse stock split.
Important Facts for Investors to Verify
- Whether and when the Board implements the reverse stock split.
- The final ratio selected within the authorized 1-for-2 to 1-for-9 range.
- The resulting number of outstanding shares and potential effects on the trading price and market liquidity.
- Any subsequent certificate-of-amendment filing or Nasdaq-related notice.
- The company’s financial condition and funding needs, which are not addressed in this filing.